ZEISS Medical Technology announced that the CLARUS 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, marking a significant expansion of advanced retinal diagnostic capabilities for Chinese ophthalmologists. The ultra-widefield fundus imaging system offers high-resolution True Color imaging with fluorescein angiography capabilities designed to enhance retinal disease diagnosis and monitoring.
Advanced Imaging Capabilities
The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera represents an advanced retinal imaging system that provides True Color, high-resolution images. The device captures 133° in a single image and up to 267° with multiple captures, offering detailed views of the retina from the macular region to the extreme retinal periphery.
"ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow."
Clinical Applications and Technology Features
Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The CLARUS 700 is equipped with both fluorescein angiography and live infrared imaging capabilities, aiding in diagnosing and monitoring retinal diseases.
The fundus imaging camera incorporates several innovative technology features designed to enhance clinical workflow:
- PrecisionFocus: Enables quick visualization of details in regions of interest
- QuickCompare: Allows comparison of pathology changes observed in past patient visits
- AutoBright: Reduces time spent adjusting images, allowing ophthalmologists to focus more on analysis
Market Impact in China
Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China, highlighted the system's potential impact on Chinese healthcare. "Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients."
Supporting Research
The clinical value of ultra-widefield imaging with the CLARUS system has been demonstrated in published research. A 2023 study published in Scientific Reports assessed early diabetic retinopathy severity using ultra-widefield Clarus imaging compared to conventional five-field and ultra-widefield Optos fundus imaging, supporting the system's diagnostic capabilities.
Company Background
Carl Zeiss Meditec AG, listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. With 5,730 employees worldwide, the Group generated revenue of €2,066.1 million in fiscal year 2023/24. The company's presence in rapidly developing economies is strengthened by the Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China.
